What is CYCC's current intrinsic value?

Based on 2 valuation methods, CYCC's average intrinsic value is $Infinity, with a range from our lowest to highest estimates. This calculation uses proven methodologies including DCF analysis, dividend discount models, and Benjamin Graham's value investing formulas to provide a comprehensive assessment of Cyclacel Pharmaceuticals, Inc.'s fair value.

Is CYCC stock undervalued or overvalued?

CYCC appears to be overvalued by NaN%. The stock is currently trading at $0.00, which is above its calculated fair value of $Infinity. This suggests limited upside potential with downside risk.

Should I buy CYCC stock?

Our valuation models indicate that CYCC appears to be "overvalued" based on current market price. This assessment is based on 2 different valuation methodologies and represents the consensus view across multiple analytical approaches. However, this valuation analysis is for informational purposes only and should not be considered investment advice. Always conduct your own research, consider your investment goals, risk tolerance, and consult with a financial advisor before making any investment decisions regarding CYCC or any other security.

Complete CYCC Stock Valuation Analysis- $Infinity Fair Value

Last updated: July 5, 2025

Comprehensive intrinsic value analysis using 2 different methodologies

CYCC Stock Valuation Executive Summary

Comprehensive CYCC stock valuation summary consolidating multiple methodologies and investment analysis

Cyclacel Pharmaceuticals, Inc. (CYCC)

Healthcare • Biotechnology

$0.00

Market Cap: $0.0B

CYCC Stock Valuation Summary - Is CYCC Undervalued or Overvalued?

Our comprehensive CYCC stock analysis uses 2 different valuation models to determine if CYCC is trading above or below its intrinsic value. Based on multiple methodologies including Discounted Cash Flow (DCF), Dividend Discount Model (DDM), and Graham's value investing formulas, we provide a data-driven assessment of CYCC's fair value.

CYCC appears to be overvalued by NaN%Trading at 0.00x its average intrinsic value with a negative margin of safety

Detailed Valuation Results by Method

Valuation Method	Intrinsic Value	Upside/Downside	Confidence
DCF- Unlevered - Perpetual Growth	$Infinity	+Infinity%	High
DCF- Unlevered - Exit Multiple	$Infinity	+Infinity%	High
DCF- Levered - Perpetual Growth	$Infinity	+Infinity%	High
DCF- Levered - Exit Multiple	$Infinity	+Infinity%	High
Peer Valuation- P/E Ratio	$-0.72	-387.9%	High
Peer Valuation- EV/EBITDA	$0.00	-100.0%	High
Peer Valuation- P/S Ratio	$0.01	-97.7%	Medium

DCF

Unlevered - Perpetual Growth

High

Intrinsic Value

$Infinity

Upside/Downside

+Infinity%

DCF

Unlevered - Exit Multiple

High

Intrinsic Value

$Infinity

Upside/Downside

+Infinity%

DCF

Levered - Perpetual Growth

High

Intrinsic Value

$Infinity

Upside/Downside

+Infinity%

DCF

Levered - Exit Multiple

High

Intrinsic Value

$Infinity

Upside/Downside

+Infinity%

Peer Valuation

P/E Ratio

High

Intrinsic Value

$-0.72

Upside/Downside

-387.9%

Peer Valuation

EV/EBITDA

High

Intrinsic Value

$0.00

Upside/Downside

-100.0%

Peer Valuation

P/S Ratio

Medium

Intrinsic Value

$0.01

Upside/Downside

-97.7%

CYCC Valuation Consensus & Key Metrics

Average Fair Value

$Infinity

Based on 2 valuation models

Median Fair Value

$Infinity

Middle value across all methods

Valuation Range

$-1 - $Infinity

Min to max intrinsic value

Investment Rating

Significantly Undervalued

NaN% above fair value

Investment Analysis Summary for CYCC

Last updated: July 5, 2025

$0.00

Current Price

$Infinity

Average Intrinsic Value

NaN%

Premium to Fair Value

Valuation Assessment:

Significantly Undervalued

Based on 2 independent valuation methodologies, providing a comprehensive assessment of CYCC's intrinsic value relative to current market price.

Frequently Asked Questions about CYCC Stock Valuation

CYCC DCF Analysis

CYCC (Cyclacel Pharmaceuticals, Inc.) discounted cash flow analysis with multiple scenarios, growth assumptions, and terminal value calculations

Financial Projections

Metrics	2022 (Historical)	2023 (Historical)	2024 (Historical)	2025 (Projected)	2026 (Projected)	2027 (Projected)	2028 (Projected)	2029 (Projected)
Revenue	$0	$420.0K	$43.0K	$38.7K	$34.8K	$31.3K	$28.2K	$25.4K
Revenue Growth %	-	Infinity%	-89.8%	-10.0%	-10.0%	-10.0%	-10.0%	-10.0%
EBIT	$-27.7M	$-25.5M	$-12.0M	$1.9K	$1.7K	$1.6K	$1.4K	$1.3K
EBIT Margin %	0.0%	-6060.2%	-27916.3%	5.0%	5.0%	5.0%	5.0%	5.0%
Tax Rate %	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%
NOPAT	$-20.7M	$-19.1M	$-9.0M	$1.5K	$1.3K	$1.2K	$1.1K	$952
NOPAT Margin %	-Infinity%	-4545.2%	-20937.2%	3.8%	3.8%	3.8%	3.8%	3.8%
Capex	$7.0K	$6.0K	$0	$387	$348	$313	$282	$254
Capex / Revenue %	Infinity%	1.4%	0.0%	1.0%	1.0%	1.0%	1.0%	1.0%
Depreciation	$32.0K	$31.0K	$6.0K	$InfinityB	$InfinityB	$InfinityB	$InfinityB	$InfinityB
D&A / Revenue %	Infinity%	7.4%	14.0%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%
Change in NWC	$-18.5M	$-17.7M	$-1.9M	$387	$348	$313	$282	$254
NWC Change / Revenue %	-Infinity%	-4222.9%	-4365.1%	1.0%	1.0%	1.0%	1.0%	1.0%
Unlevered FCF	$-2.2M	$-1.3M	$-7.1M	$InfinityB	$InfinityB	$InfinityB	$InfinityB	$InfinityB
UFCF % Chg.	-	39.8%	-435.8%	Infinity%	NaN%	NaN%	NaN%	NaN%
FCF / Revenue %	-Infinity%	-316.4%	-16558.1%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%
Discount Factor	-	-	-	0.949	0.901	0.856	0.812	0.771
Present Value of FCF	-	-	-	$InfinityB	$InfinityB	$InfinityB	$InfinityB	$InfinityB
Sum of PV of UFCF	-	-	-	$InfinityB	$InfinityB	$InfinityB	$InfinityB	$InfinityB

WACC Calculation

Weighted Average Cost of Capital used for discounting cash flows.

WACC Calculation	Value
Cost of Debt	6.8%
Tax Rate	25.0%
After Tax Cost of Debt	5.1%
Risk Free Rate	4.26%
Market Risk Premium	4.3%
Beta	0.25
Cost of Equity	5.3%
Total Debt	$0
Market Cap	$5.9M
Total Capital	$5.9M
Debt Weighting	0.0%
Equity Weighting	100.0%
WACC	5.3%

Terminal Value

Choose between perpetuity growth or exit multiple methods.

Terminal Value Calculation	Value
Terminal Growth Rate	2.5%
Final Year FCF	$InfinityB
Terminal Value	$InfinityB
PV of Terminal Value	$InfinityB
Cumulative PV of UFCF	$InfinityB
Net Debt	$-3.1M
Equity Value	$InfinityB
Shares Outstanding	5.4M
Implied Share Price	$InfinityB
Current Share Price	$0
Implied Upside/(Downside)	+Infinity%

Valuation Summary

$Infinity

Implied Price

$0.25

Current Price

+Infinity%

Upside/Downside

5.3%

WACC

CYCC Peer Valuation Analysis

Relative valuation based on comparable company trading multiples

Peer Valuation Analysis

Fair Value Range Analysis

Based on median multiples from 7 peer companies in Healthcare

P/E Ratio

$-0.72

-387.9%

Peer Median: 0.6x

EV/EBITDA

$0.00

-100.0%

Peer Median: 0.0x

P/S Ratio

$0.01

-97.7%

Peer Median: 4.7x

Interpretation: Each multiple provides a different perspective on fair value. Consider which multiple is most relevant for CYCC's business model and current situation.

Multiple Comparison

Multiple	CYCC Current	Peer Median	Peer Average	Premium/Discount	Assessment
P/E Ratio	-0.2x	0.6x	0.6x	-134.7%	Undervalued
EV/EBITDA	Infinityx	0.0x	0.0x	Infinity%	Overvalued
P/S Ratio	204.7x	4.7x	6.2x	4216.7%	Overvalued

Peer Companies

Click any company to view their valuation

Company	Market Cap	P/E Ratio	EV/EBITDA	P/S Ratio
AVTX Avalo Therapeutics, Inc.	$0.05B	0.6x	0.0x	122.9x
SPRO Spero Therapeutics, Inc.	$0.16B	0.0x	0.0x	4.7x
CYCC Cyclacel Pharmaceuticals, Inc.	$0.01B	0.0x	0.0x	1244.2x
ESLA Estrella Immunopharma, Inc.	$0.03B	0.0x	0.0x	0.0x
ACRV Acrivon Therapeutics, Inc. Common Stock	$0.04B	0.0x	0.0x	0.0x
ALGS Aligos Therapeutics, Inc.	$0.04B	0.0x	0.0x	13.6x
FGEN FibroGen, Inc.	$0.02B	0.0x	0.0x	0.2x